Shapiro GI - Search Results

1

The evolving role of cyclin-dependent kinase inhibitors in cancer management.

Shapiro GI. Shapiro GI. Clin Adv Hematol Oncol. 2017 Mar;15(3):174-177. Clin Adv Hematol Oncol. 2017. PMID: 28398270 No abstract available.

2

A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.

Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ Jr, Rollins BJ. Shapiro GI, et al. Clin Cancer Res. 2001 Jun;7(6):1590-9. Clin Cancer Res. 2001. PMID: 11410495 Clinical Trial.

3

Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.

Jiang J, Matranga CB, Cai D, Latham VM Jr, Zhang X, Lowell AM, Martelli F, Shapiro GI. Jiang J, et al. Among authors: shapiro gi. Cancer Res. 2003 Nov 1;63(21):7410-22. Cancer Res. 2003. PMID: 14612540

4

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.

Shapiro GI. Shapiro GI. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4270s-4275s. doi: 10.1158/1078-0432.CCR-040020. Clin Cancer Res. 2004. PMID: 15217973 Review.

5

AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.

Cai D, Byth KF, Shapiro GI. Cai D, et al. Among authors: shapiro gi. Cancer Res. 2006 Jan 1;66(1):435-44. doi: 10.1158/0008-5472.CAN-05-1769. Cancer Res. 2006. PMID: 16397259

6

Cyclin-dependent kinase pathways as targets for cancer treatment.

Shapiro GI. Shapiro GI. J Clin Oncol. 2006 Apr 10;24(11):1770-83. doi: 10.1200/JCO.2005.03.7689. J Clin Oncol. 2006. PMID: 16603719 Review.

7

Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.

Cai D, Latham VM Jr, Zhang X, Shapiro GI. Cai D, et al. Among authors: shapiro gi. Cancer Res. 2006 Sep 15;66(18):9270-80. doi: 10.1158/0008-5472.CAN-06-1758. Cancer Res. 2006. PMID: 16982772

8

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.

Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, Schellens JHM, Shapiro GI. Boss DS, et al. Among authors: shapiro gi. Ann Oncol. 2010 Apr;21(4):884-894. doi: 10.1093/annonc/mdp377. Epub 2009 Oct 13. Ann Oncol. 2010. PMID: 19825886 Free PMC article. Clinical Trial.

9

Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer.

Cleary JM, Shapiro GI. Cleary JM, et al. Among authors: shapiro gi. Curr Oncol Rep. 2010 Mar;12(2):87-94. doi: 10.1007/s11912-010-0091-6. Curr Oncol Rep. 2010. PMID: 20425592 Free PMC article. Review.

10

Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors.

Johnson N, Shapiro GI. Johnson N, et al. Among authors: shapiro gi. Expert Opin Ther Targets. 2010 Nov;14(11):1199-212. doi: 10.1517/14728222.2010.525221. Expert Opin Ther Targets. 2010. PMID: 20932174 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

294 results

Search Page